Chronic neutrophilic leukemia diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Chronic neutrophilic leukemia}} {{CMG}}; {{AE}} == Overview == == Diagnostic Study of Choice == === Study of choice === [Name of the investigation] is the gold s...")
 
m (Bot: Removing from Primary care)
 
(17 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Chronic neutrophilic leukemia}}
{{Chronic neutrophilic leukemia}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}} {{Homa}}; {{GRR}} {{Nat}}
== Overview ==
== Overview ==
[[World health organization]] [[(WHO)]] introduces [[criteria]] for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the [[laboratory]] finding of [[peripheral blood cells]], [[bone marrow]], cytogenic [[mutation]], and [[differential diagnosis]].


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==


=== Study of choice ===
=== Study of choice ===
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
The [[diagnosis]] of CNL is based on the [[WHO]] criteria, which include:<ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref>


OR
{|
 
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |World Health Organization (WHO) Criteria for CNL diagnosis
The following result of [gold standard test] is confirmatory of [disease name]:
|-
* [Result 1]
! style="background: #DCDCDC; text-align: center;" |1. [[Peripheral blood]] [[White blood cells]] [[(WBC)]] ≥25 ×10<sup>9</sup>/L:
* [Result 2]
| style="background: #F5F5F5;" |
 
* Segmented [[neutrophils]] plus [[Band cell|band]] forms ≥80% of [[WBC]]
OR
* [[Neutrophil]] [[Precursor|precursors]] <10% of WBC
 
* [[Myeloblast|Myeloblasts]] rarely observed
[Name of the investigation] must be performed when:
* [[Monocyte]] count <1 ×10<sup>9</sup>/L
* The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
* No dysgranulopoies.
* A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
|-
 
! style="background: #DCDCDC; text-align: center;" |2. Hypercellular [[bone marrow]]:
OR
| style="background: #F5F5F5;" |
 
* [[Neutrophil granulocytes]] increased in percentage and number
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
* Normal [[neutrophil]] [[maturation]]
 
* [[Myeloblast|Myeloblasts]] <5% of [[nucleated]] cells
OR
|-
 
! style="background: #DCDCDC; text-align: center;" |3. Not meeting [[WHO]] criteria for:
The diagnostic study of choice for [disease name] is [name of the investigation].
| style="background: #F5F5F5;" |
 
* BCR-ABL1+ [[chronic myeloid leukemia]],
OR
* [[Polycythemia vera]]
 
* [[Essential thrombocythemia]]
There is no single diagnostic study of choice for the diagnosis of [disease name].
* [[Primary myelofibrosis]]
 
OR
 
There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
 
OR
 
[Disease name] is primarily diagnosed based on the clinical presentation.
 
OR
 
Investigations:
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
 
==== The comparison of various diagnostic studies for [disease name] ====
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Test
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Sensitivity
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specificity
|-
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 1
! style="background: #DCDCDC; text-align: center;" |4. No rearrangement of:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="background: #F5F5F5;" |
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
* PDGFRA
* [[PDGFRB]]
* [[FGFR1]]
* PCM1-JAK2
|-
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 2
! colspan="2" style="background: #DCDCDC; text-align: center;" |
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
5.Presence of CSF3RT618I or other activating [[CSF3R]] [[mutation]] or In the absence of a CSFR3R [[Mutation|mutation,]] persistent [[neutrophilia]] (at least 3 months), [[splenomegaly]], and no identifiable cause of reactive [[neutrophilia]] including the absence of a [[plasma cell neoplasm]] or, if present, demonstration of clonality of [[myeloid cells]] by [[cytogenetic]] or [[molecular]] studies.
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|}
|}
<small> [Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity</small>
===== Diagnostic results =====
The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:
* [Finding 1]
* [Finding 2]
===== Sequence of Diagnostic Studies =====
The [name of investigation] must be performed when:
* The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
* A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
* [Initial investigation]
* [2nd investigation]
=== Name of Diagnostic Criteria ===
'''It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.'''
[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
OR
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:
* Criteria 1
* Criteria 2
* Criteria 3
OR
'''IF there are clear, established diagnostic criteria'''
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
'''IF there are no established diagnostic criteria'''
There are no established criteria for the diagnosis of [disease name].


==References==
==References==
Line 130: Line 49:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
]
[[Category:Up-To-Date]]
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 20:57, 29 July 2020

Chronic neutrophilic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Chronic neutrophilic leukemia from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic neutrophilic leukemia diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic neutrophilic leukemia diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic neutrophilic leukemia diagnostic study of choice

CDC on Chronic neutrophilic leukemia diagnostic study of choice

Chronic neutrophilic leukemia diagnostic study of choice in the news

Blogs on Chronic neutrophilic leukemia diagnostic study of choice

Directions to Hospitals Treating Chronic neutrophilic leukemia

Risk calculators and risk factors for Chronic neutrophilic leukemia diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

World health organization (WHO) introduces criteria for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the laboratory finding of peripheral blood cells, bone marrow, cytogenic mutation, and differential diagnosis.

Diagnostic Study of Choice

Study of choice

The diagnosis of CNL is based on the WHO criteria, which include:[1]

World Health Organization (WHO) Criteria for CNL diagnosis
1. Peripheral blood White blood cells (WBC) ≥25 ×109/L:
2. Hypercellular bone marrow:
3. Not meeting WHO criteria for:
4. No rearrangement of:

5.Presence of CSF3RT618I or other activating CSF3R mutation or In the absence of a CSFR3R mutation, persistent neutrophilia (at least 3 months), splenomegaly, and no identifiable cause of reactive neutrophilia including the absence of a plasma cell neoplasm or, if present, demonstration of clonality of myeloid cells by cytogenetic or molecular studies.

References

  1. ↑ Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.

Template:WH Template:WS ]

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_neutrophilic_leukemia_diagnostic_study_of_choice&oldid=1636095"